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INTRODUCTION
Dementia refers to a range of disorders characterized
by declining memory, multiple cognitive deficits and
eventual mortality due to progressive and irreversible
brain damage1. Disease entities comprising dementia
characteristically affect mainly the geriatric population.
Together, they constitute a major component of global
disease burden in general and geriatric disease burden
in particular2. In 2005, it was estimated that 24.3
million people in the world were living with dementia;
4.6 million cases have been added each year ever
since3. Overall, dementia contributes 11.3% of years
of life lived with disability, making it a major contributor
to worldwide morbidity4.
As the world's sixth most populous country, Pakistan
faces a stiff challenge of managing an aging population
in the years ahead.
Table 1: Geriatric Burden in Pakistan5, 6

Parameter

Current

Projected

65+ Population

8 million

27 million (2050)

Old-age dependence ratio*

8.8/100

23.7/100 (2060)

*(number of 65+ individuals for every hundred working-individuals aged 20-64)
According to the Delphi consensus study3, the
prevalence of dementia in South Asia is estimated to
be 1.9%. These numbers imply that presently more
than 150,000 people are living with dementia in the
country. Evidently, this number is anticipated to grow
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rapidly in the next few decades. This constitutes a
looming public health as well as socioeconomic challenge
that require tailored and systematic planning keeping
in view the economic, cultural and healthcare paradigm
that we live in.
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2. PROPOSAL & METHODS

These guidelines are not only targeted towards local
primary care physicians but will also be a useful reference
at all levels of practice. An effort has been made to
include only the most relevant aspects of dementia
care. Annual updates will be undertaken as more
relevant evidence becomes available.

Dementia in Pakistan has so far been grossly
under-studied. No population based-study has been
undertaken to date and data on clinical characteristics
is scarce. This makes formulation of evidence-based
national guidelines a tough task. Regardless, a clinical
guideline is paramount to enable efficient and proper
management of patients currently under care for or
presenting with dementia at primary, secondary and
tertiary care facilities across the country. For this purpose,
the authors used currently available tools to review
relevant data on epidemiology, diagnosis, management
and follow-up care of dementia as well as International
guidelines published worldwide, particularly those from
developing countries. Special attention was given to
World Alzheimer's report 2011, Cochrane reviews, the
current issue of Continuum and NICE guidelines
4, 7, 8, 9 .The authors also analyzed clinical data from
their own registry of dementia patients presenting to
a tertiary care center.

3. RECOGNIZING DEMENTIA
Lack of awareness about dementia is quite common
in both the general population as well as the physician
workforce. The latter may be due to a lack of focus on
geriatric medical education in medical schools which
in turn leaves medical practices to be dictated by
personal and cultural experiences 10 .Detection of
differences between normal aging and dementia then
becomes rather difficult for the non-discerning eye.
Differences usually elicited by a thorough history at the
primary care level are listed the table 2 below11.

Table 2: Clinical differences between normal aging and Dementia
NORMAL AGING

DEMENTIA

Independent in all activities of daily living (ADL)

Dependent on others for ADL

Patient claims of memory loss but can recall
incidents of forgetfulness

May report memory loss if asked, unable to
recall instances of forgetfulness

Patient more concerned about memory loss

Close family members more concerned
about memory loss

Recent memory of events and conversations intact

Notable decline in memory of recent events
and conversations

Occasional difficulty in finding words
(expressive aphasia)

Frequently experiences difficulty in finding words with
or without difficulty of understanding
(expressive and receptive aphasia)

No history of getting lost in familiar territory,
may pause briefly to reorient

History of getting lost in familiar territory while
walking or driving

Able to operate common appliances

Unable to operate common appliances

Normal interpersonal and social skills

Loss of interpersonal and social skills, lack of interest
in social activities or inappropriate behavior

Due to lack of awareness in the general population,
caregivers are highly likely to mistake dementia for agerelated cognitive decline and fail to report it to doctors
12, 13. Due to small number of specialist physicians and
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limited access to specialist care, primary care physicians
(PCP) should play key role in the recognition, diagnosis,
and management of patients with dementia.
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RECOMMENDATION

sufficiently severe to cause impairment in occupational
or social functioning and must represent a decline from
a previously higher level of functioning 1 4 .

PCPs should learn how to assess patients with
early signs of dementia.

Once a possible diagnosis of dementia is suspected
on history, a full cognitive, mental, medical and physical
evaluation should be undertaken.

A focused history concerning mental function
should be undertaken during all geriatric outpatient
visits to aid early detection, diagnosis and
symptomatic relief.

Clinical cognitive examination of attention and
concentration, orientation, short and long-term memory,
praxis, language and executive function can be
accomplished using a standardized instrument like
MMSE. Urdu translations of MMSE are currently
undergoing validation. Interpreting MMSE score should
take in to account factors known to affect performance,
including educational level, skills, prior level of
functioning, language, any sensory impairments,
psychiatric illness or physical/neurological problems9.
A score ?26 is usually considered normal, a score of
20-25 indicates mild, 10-19 moderate and
< 10 severe dementia (Table 3). Another screening
tool that can

Seminars, workshops and public awareness
sessions should be arranged to increase awareness
about dementia and its impact on physical and
social functioning
4.

DIAGNOSING DEMENTIA

The DSM IV definition of dementia is comprehensive
and is widely acceptable for making a diagnosis of
dementia. The development of multiple cognitive deficits
that include memory impairment and at least one of
the following: aphasia, apraxia, agnosia, or a disturbance
in executive functioning. These deficits must be

Table 3. Stages and Progression of Dementia
Stages
Preclinical :

Symptoms
No symptoms. This stage of Alzheimer's can last for years, possibly
even decades. New imaging technologies and biomarkers may detect
disease during this stage.

Mild cognitive impairment (MCI) :
Score > or = 26

Mild changes in their memory and thinking ability but changes MMSE
not significant enough to affect work or relationships yet.
May have memory lapses, problems with judgment and time
management and decision making.

Mild dementia:
MMSE Score: 20-25

Alzheimer's disease is often diagnosed in the mild dementia stage,
when there is significant trouble with memory, thinking, organizing,
expression, problem-solving, complex tasks and sound judgments.
Changes in personality. Getting lost or misplacing belongings

Moderate dementia
MMSE Score: 10-19

Poor judgment and deepening confusion, loss of orientation of place,
time and person. Greater memory loss, forget their address or phone
number, personal belongings. They repeat favorite stories or make
up stories. Need help with some daily activities and develop
incontinence of urine and bowels. Significant changes in personality
and behavior. May hallucinate and become restless or agitated.

Severe dementia
MMSE Score: < 10

Further decline in cognitive and phys ical capabilities. Lose the ability
to communicate or speak coherently. Require daily assistance with
personal care, eating, dressing, walking and toileting. Later, there
is loss of swallowing and control of bladder and bowels, ultimately
leading to a bedbound vegetative state.
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be used is Mini-Cognitive Assessment tool (Mini-Cog)
with the same sensitivity and specificity as that of
MMSE. Montreal Cognitive Assessment (MoCA) assesses
multiple cognitive domains and has low susceptibility
to educational and cultural bias. Ascertain Dementia
(AD8) is an informant based screening tool that assesses
memory, orientation, function and judgment. Use of
AD8 can improve detection of dementia in primary
setting to 97% for dementia and 91% for MCI.
Daily functional assessment of patients can be done
by interviewing and using ADL scale. More advance
functioning like shopping, managing finances can be
assessed by instrumental ADLs (IADLs). Functional
Assessment Questionnaire (FAQ) can also be used to
assess more complex activities.

differentiate different types of dementia. MRI is preferable
over CT brain. For rapidly progressive dementia the MRI
should include DWI and ADC sequence. Functional
imaging is recommended only in cases where diagnosis
is in doubt after clinical and structural imaging and in
special circumstances15

Neuropsychiatric evaluation should be conducted for
detection of coexisting depression, psychosis, agitation
and other complaints. The Neuropsychiatric Inventory
Questionnaire (NPI-Q) is a quickly administered
instrument that provides reliable assessment of behaviors
commonly observed in patients with dementia.
Investigations warranted to rule out medical causes of
cognitive impairment include serum electrolytes, calcium,
magnesium, phosphate, glucose, liver & renal function
tests, TSH, B12 and folate levels. Cognitive impairment
of acute onset in the setting of medical illness is
suggestive of delirium and should be ruled out as well.
Neuroimaging should be performed in the diagnostic
work up to exclude other potentially treatable causes
of dementia, to look for vascular lesions and to

RECOMMENDATIONS

Routine medications known to cause memory
impairmen11 should be accounted for. These include
anti-histamines (both H1 & H2 blockers), Digoxin, anticholinergics, anti-convulsants (phenytoin, valproic acid,
carbamazepine), tricyclic antidepressants, beta-blockers,
alpha-blockers, calchium-channel blockers, Lithium,
typical anti-psychotics and anti-Parkinsonian agents
(L-dopa, pergolide, bromocriptine)

For cognitive assessment screening tools like
MMSE, Mini-Cog should be used. If MMSE is
used, the educational background of the patient
should be documented as well for accurate
interpretation of MMSE.
Common treatable causes of memory loss like
vitamin B12 deficiency, hypothyroidism and normal
pressure hydrocephalus should be ruled out.
Neuro-imaging, preferably an MRI of the brain
should be done in order to reach a reasonably
accurate diagnosis. For rapidly progressive dementia
the MRI should include DWI and ADC sequences.

5. DIFFERENTIATING DEMENTIA
Features of different disease entities comprising dementia are listed in Table 4.
Table 4: Major disease entities comprising dementia are listed. All diagnoses of dementia require that deficits must
represent a decline from previous function and must lead to impairment in performing ADLs. Other causes that may
account for these symptoms must always be excluded first.
Disease
(Criteria Source)

Diagnostic Criteria

Alzheimers
(DSM-IV)

Objectively demonstrated memory deficit PLUS at least one of the following:
Aphasia (abnormal speech)
Executive function impairment (difficulty planning, judgment, abstraction, problem-solving etc)
Agnosia (impaired recognition of people or objects)
Apraxia (impaired performance of learned motor skills)
Clinical features: Symptomatic course is gradual and progressive.
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Vascular Dementia
(NINDS  AIREN)

Focal neurological signs on exams consistent with stroke AND evidence of CVD on brain imaging
(CT or MRI) PLUS at least one of the following:
Onset of dementia within 3 months following a recognized stroke
Abrupt deterioration in cognitive function Stepwise progression of cognitive deficit
Clinical features: early presence of gait disturbance; history of unsteadiness and frequent,
unprovoked falls; early urinary frequency, urgency, and other urinary symptoms not explained
by urologic disease; pseudo-bulbar palsy; personality and mood changes, abulia, depression,
emotional incontinence, or other subcortical deficits including psychomotor retardation

Lewy Body
(ICC for DLB)

Two of the following are required for a diagnosis of probable Dementia with Lewy bodies:
Fluctuating cognition with pronounced variations in attention and alertness
Recurrent visual hallucinations which are typically well-formed and detailed
Spontaneous motor features of Parkinsonism
Clinical features: Prominent deficits in attention, visuospatial ability and fronto-subcortical skills;
history of falls & syncope; systematized delusions and hallucinations worsened by neuroleptics

FrontoTemporal Dementia
(Lund-Manchester)

ALL of the following must be present:
Insidious onset and gradual progression
Early decline in social interpersonal conduct
Early impairment in regulation of personal conduct
Early emotional blunting
Early loss of insight
Clinical features: Usually presents in middle-age with behavioral, speech, personality and conduct
issues. Memory is often minimally impaired early on. Frontal lobe signs including primitive
reflexes, akinesia and incontinence may be evident

Parkinsons
Dementia
(EMRE et al)

Core criteria: Previously diagnosed Parkinsons disease presenting with dementia.
Supportive features: Typical profile of cognitive impairment plus behavioral symptoms including
apathy, depressed or anxious mood, hallucinations, delusions, excessive daytime sleepiness
etc).

Normal Pressure
Hydrocephalus

Triad of gait disturbance, urinary complaints and cognitive impairment should raise suspicion
of NPH. Early cognitive deficits include psychomotor slowing, impaired attention and executive
& visuospatial dysfunction.

Crautzfeldt-Jacob
Disease
(MRI-CJD
Consortium)

Rapidly progressive dementia AND at least two out of the following four clinical features:
Myoclonus
Visual or Cerebellar signs
Pyramidal/extrapyramidal signs
Akinetic mutism
AND a positive result on at least one of the following laboratory tests:
Typical EEG (periodic sharp wave complexes) during an illness of any duration; and/or
Positive 14-3-3 CSF assay in patients with a disease duration of less than 2 years
MRI high signal abnormalities in caudate nucleus and/or putamen on DWI or
FLAIR sequence

Mixed Type

PAKISTAN

JOURNAL

Hallmark abnormalities of Alzheimers along with features of others, most commonly Vascular
and Lewy Body dementias. Note that Alzheimers should not be diagnosed in the presence of
evidence of significant CVD

OF

NEUROLOGICAL

SCIENCES

21

VOL.

8(3) JULY - OCT 2013

6. MANAGING DEMENTIA

32 mg per day) resulted in significant cognitive
improvement on the Alzheimer's disease Assessment
Scale-Cognitive Subscale (ADAS-Cog), a clinician's
global assessment, theactivities of daily living scale,
and a behavior scale. Efficacy was present at 16 mg/day
and 24 mg/day. Side effects occurred in up to 13% at
16 mg per day and up to 17% of subjects exposed to
24 mg per day.28, 29 Memantine, an NMDA receptor
antagonist, improved cognition and global functioning
in two poorly defined groups of patients with
dementia.30, 31

6.1. Pharmacological management
6.1.1. Symptomatic Treatment
Although studies suggest a small degree of benefit
clinically, cholinesterase inhibitors should be considered
in patients with mild to moderate Alzheimer's.
In three double-blind placebo-controlled trials, donepezil
produced a significant improvement lasting 3 to 6
months on both a composite test and a clinician's
global evaluation in individuals with both Alzheimer's &
vascular dementia. Efficacy has been demonstrated at
doses of both 5 and 10 mg; a5 mg QD dose can be
increased to 10 mg QD after 4 to 6 weeks. Side effects
occurred in up to 17% of subjects exposed to the drug.
Six studies have reported a dose-response effect with
increasing frequency of adverse events as dosage
16, 17, 18, 19, 20, 21. Nine adverse events had statistically
significant effect sizes in patients with Alzheimer disease;
diarrhea (relative risk, 2.57) and nausea (relative risk,
2.54) were reported most frequently. For patients with
vascular dementia, abnormal dreams, diarrhea, nausea,
and muscle and leg cramps were statistically significant;
muscle cramps had the largest effect size (relative risk,
9.62), and nausea had the smallest (relative
risk, 2.21).

A pooled estimate from 3 trials showed that 20 mg/d
memantine resulted in statistically significant
improvement on the ADAS-cog scale in cognition for
individuals with mild to moderate vascular
dementia 32, 33 and mild to moderate Alzheimer disease34.
In addition, patients with moderate to severe Alzheimer
disease showed statistically significant improvement
on the SIB scale 35, 36. However, patients with mixed
dementia had no difference37. Three of four studies
that evaluated quality of life found statistically significant
improvements, and the summary estimate was
statistically significant. Two trials evaluated caregiver
burden and resource utilization and found statistically
significant improvements on both parameters.
Two of the 6 eligible studies reported information on
the proportion of patients who had a clinically important
improvement on memantine. Only one of these trials
reported statistical significance, and that trial did not
find a statistically significant change.

Treatment with rivastigmine for 6 months resulted in
significant differences compared with placebo in cognition
and on a clinician's global assessment and an activities
of daily living scale22, 23, 24. Higher doses (6 to 12 mg
per day) yielded better outcomes than lower doses (1
to 4 mg per day), which were no better than placebo
in one study. Side effects (including weight loss) were
present in up to half of those in higher-dose groups
and led to discontinuation of the drug in up to a quarter.
The initial dose is 1.5 mg BID, which can be increased
to 3 mg BID, then 4.5 mg BID, then 6 mg BID with a
minimum of 2 weeks intervening period between
increases. The rivastigmine transdermal patch
formulation when compared to the rivastigmine capsule
showed a less fluctuating and a more continuous drug
delivery and improved tolerability 25. Another study of
the 9.5 cm2 Rivastigmine patch showed similar efficacy
to capsules 6mg BID) with approximately two-thirds
fewer reports of nausea and vomiting26. Recently a
13.3mg rivatigmin transdermal patch has been approved
by FDA27

The withdrawal rates related to adverse effects from
memantine including nausea, dizziness, diarrhea, and
agitation varied from 9% to 12% in the treatment group
(7% to 13% in the placebo group).
COMPARATIVE EFFECTIVENESS
DONEPEZIL VERSUS GALANTAMINE
Two studies compared donepezil (10 mg/d) with
galantamine 38, 39, focusing on Alzheimer disease, with
one describing severity of dementia as mild to moderate.
The results from the longer study (52 weeks) showed
no statistical differences in the primary outcome of
function. However, changes in secondary outcomes of
cognition (measured with the ADAS-cog and MMSE)
showed statistical differences favoring galantamine in
patients with MMSE scores between 12 and 18 only.
The most frequently reported adverse events were
nausea, agitation, vomiting, headache, and falls. The
rates for adverse events were marginally higher for
galantamine but were not statistically evaluated. Serious

Galantamine was tested in more than 1,600 subjects
with mild to moderate AD in two double-blind, placebocontrolled studies. Treatment with galantamine (16 to
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adverse events did not differ between galantamine and
donepezil.

There is one ongoing phase II trial in moderate to severe
dementia to determine benefit of curcumin (found in
turmeric) in slowing cognitive deterioration. 4 6
Several studies have also showed possible link between
vitamin D deficiency and cognitive decline. However
further trials are needed to establish a casual
relationship.47, 48

DONEPEZIL VERSUS RIVASTIGMINE
One large trial compared donepezil (up to 10 mg/d for
2 years) with rivastigmine (up to 12 mg/d for 2 years)
and focused on patients with moderately severe
Alzheimer disease for more than 2 years 40, 41 .The
results statistically significantly differed in global function
(Global Deterioration Scale) and function (Alzheimer
disease Co-operative Study-Activities of Daily Living
Scale), favoring rivastigmine. A subgroup analysis of
patients age 75 years or older versus those younger
than 75 years showed statistical differences in some
measures of behavior and function, favoring rivastigmine.
Comparison of adverse events showed that rivastigmine
had higher rates of nausea during titration and
maintenance phases. In general, patients receiving
rivastigmine reported more adverse events than those
receiving donepezil, but no differences in serious events
were observed.

Trials evaluating extracts of the leaves of the maidenhair
tree, Ginkgo biloba, that has been used in China for
long time for cognitive impairment have shown conflicting
results and Chochrane review has concluded that the
benefits of Ginkgo biloba in memory impairment are
inconsistent49. Similar conclusions have been drawn
for ginseng 5 0 , hydergine 5 1 and piracetam 5 2 .
The World Alzheimer Report 2011 53 in its comprehensive
analysis of the Cochrane systemic review concluded
that there is no evidence to recommend the use of
nutritional supplements at any stage of dementia
RECOMMENDATIONS
The decision to initiate a trial of therapy with a
cholinesterase inhibitor or memantine should be
made by the treating physician based on
individualized assessment.
Cholinesterase inhibitors are recommended for
mild to moderate disease. No specific cholinesterase
inhibitor is recommended over another.
Memantine and donepezil is recommended for
moderate to severe disease. Combination therapy
was also found to be safe and tolerable in moderate
to severe disease
At present there is no evidence that support the
use of ginkgo biloba, ginseng, hydergine and
piracetam in the treatment of dementia
Presently the evidence does not support the use
of nutritional suppliments for the treatment of
dementia

COMBINING MEMANTINE WITH A CHOLINESTERASE
INHIBITOR
In one study, addition of NMDA receptor antagonist
memantine to cholinesterase inhibitors (tacrine,
donepezil, rivastigmine and galantamine) delayed
admission to nursing home 42. A systemic review
43 .comparing the efficacy of acetyl cholinesterase
inhibitor (aChEI) monotherapy with combination of
memantine and aChEI therapy in moderate to severe
AD showed a small benefit at 6 months.
6.2. NON-PHARMACOLOGICAL TREATMENT/DIETARY
SUPPLEMENTS VITAMIN E, FOLATE AND OTHER
NUTRIENTS

In one large, 2-year trial, selegiline (5 mg BID) and
vitamin E (1,000 I.U. [alpha-tocopherol] BID) significantly
delayed the time to a composite outcome of primary
measures indicative of clinical worsening, and fewer
patients treated with vitamin E were institutionalized44
Importantly, however, there was no additive effect from
selegiline plus vitamin E, neither agent improved cognitive
function (ADAS-Cog) compared with baseline values,
and those on drug did not decline less than those on
placebo on these types of measures. Similarly there
are no clinical trials to support a recommendation of
dietary and supplemental omega-3 polyunsat urated
fatty acid for the sole purpose of preventing cognitive
impairment or dementia.45

6.3. PSYCHOLOGICAL AND BEHAVIORAL ISSUES
IN DEMENTIA
The most common behavioral symptoms are agitation,
aggression, depression, apathy, psychosis and
hallucinations, which are more disturbing to family and
care givers than memory disturbances. Common triggers
are pain, fecal impaction, acute medical illness,
boredom, loneliness, depression, and social and
environmental stressors.
6.3.1. NON-PHARMACOLOGICAL INTERVENTIONS
Non-pharmacological interventions include redirecting
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and refocusing the patient, increasing social interaction,
initiating enjoyable activities, establishing regular sleep
habits, eliminating sources of conflict and frustration,
and establishing rewards for successes.54 Cognitive
behavioral therapy may help clinician understand
patient's needs and thus tailor the treatment
accordingly.55

to the patient and family it is also important to discuss
issues of advance directives and the patient should
update his or her will before the patient loses his
capacity to disclose his or her wishes on these matters.
3. GENETICS AND GENETIC TESTING OF
ALZHEIMERS DISEASE AND FRONTAL LOBE
DEGENERATION

6.3.2. PHARMACOLOGICAL MANAGEMENT

Advancements in neurogenetics have led to identification
of several genes for Alzheimers disease. These include
mutations in the Amyloid Precursor protein gene (APP
gene) and mutations in the Presenilin 1 gene (PSEN1)
which are the most common cause of Familial AD. The
PSEN1 mutations tend to cause young onset AD.
Mutations in the Presenilin 2 gene are rare and tend
to cause the older onset of disease. Apolipoprotein E
(Apo E) is a protein involved in lipid transport and its
prevalence in individuals with AD is around 50%,
whereas in the general population its prevalence ranges
from 15%-20%.60 Individuals with two copies of Apo
E4 increase the risk of younger onset AD. The prevalence
of Apo E4 gene in our population is unknown. As there
is no cure or prophylaxis for AD, genetic testing for AD
is not routinely recommended. The same goes for
biomarker testing in normal individuals with a family
history of AD, since a positive test may lead to
psychological issues and distress. Three genes have
been mainly found to be responsible for Frontotemporal
lobe degeneration (FTD). Two genes, both located on
17q21: the microtubule associated protein tau (MAPT)
and the progranulin (GRN) genes are responsible for
10%-20% of cases of familial FTD. Recently in 2012
two groups simultaneously published the discovery of
another gene; a hexanucleotide repeat expansion in
Chromosome 9p (CRORF72) in families with FTD and
amyotrophic lateral sclerosis (ALS).61,62 Similarly for
the same reasons as in AD, genetic testing for FTD
should not be contemplated without genetic counseling.

Pharmacological treatment is required when patient
does not respond to non-pharmacological interventions.
Commonly used agents are antipsychotics both typical
and atypical, antidepressants and mood stabilizing
agents. A metaanalysis of 3353 patients randomized
to study drug showed a 50% increase in risk of death
from all causes with no difference in risk in the studied
agents. It is recommended that drugs should only be
used when non pharmacological interventions fail to
improve symptoms.56
Tricyclic antidepressants and benzodiazepines are
generally avoided in patients with dementia. 57
Low dose trazodone, carbamezapine, valproate and
SSRIs like citalopram are found to be effective in
treatment of agitation58. Selective serotonin inhibitors
(SSRIs) are also found to be effective in the treatment
of depression.59
RECOMMENDATIONS
Non pharmacological interventions should be tried
first for the management of psychological and
behavior issues in patients with dementia
Atypical antipsychotics, low dose trazodone,
valproate, carbamezapine and SSRIs can be used
in the treatment of agitation and other psychological
issues
1.

PATIENT SAFETY ISSUES

RECOMMENDATION

Patient safety should be assessed and any gap should
be addressed on follow up visits for all dementia patients.
Common safety issues that can lead to significant
morbidity and even mortality are presence of sharp
object within easy reach, slippery floor, loose throw
rugs, poor lighting etc. Driving is contraindicated for
demented patients as they have poor reasoning and
safety awareness as well as impaired ADLs and
instrumental activities of daily living (IADL).
2.

Genetic testing for normal individuals with a family
history of AD or FTD is not routinely recommended
due to unavailability of disease modifying treatment
and the psychological stress and distress it may
cause.
4.

Caregivers of patients with dementia often suffer from
depression and long term social support to them help
improve their symptoms.63 Our own study (unpublished
data) showed that 123 out of 125(98.4%) primary

ADVANCE DIRECTIVES AND WILL

When the diagnosis of dementia is made and disclosed
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caregivers reported some level of distress. So, caregiver
distress is a prevalent problem in our setting and is
significantly dependent on the behavioral and psychiatric
symptoms of dementia

made by the treating physician based on
individualized assessment.
The choice of pharmacologic agents should be
based on tolerability, adverse effect profile, ease
of use, and cost of medication. The evidence is
insufficient to compare the effectiveness of different
pharmacologic agents or their combinations, for
the treatment of dementia.
Genetic testing for AD and FTD in normal
individuals/family members of affected patients is
not routinely recommended

RECOMMENDATION
Care givers should be given assistance and guidance
in care giving and periodic assessment of their
own health should be performed.
5.

MILD COGNITIVE IMPAIRMENT

REFERENCES

Having discussed all aspects of dementia pertinent to
our population, it is worth mentioning that when
measurable criteria for dementia(e.g. MMSE) are not
met, yet the patient complains of progressive cognitive
decline without impairment of ADL's, the term mild
cognitive impairment(MCI) may be used (Table 3). This
group encompasses patients who later on would progress
to dementia, especially AD and also those suffering
from psychiatric disorders (pseudo-dementia), systemic
illness or senility, who do not progress to dementia.
The most acceptable criteria for MCI includes four
subgroups; (a) deficits in memory alone, (b) deficits in
memory plus deficits in another cognitive domain, (c)
deficits in a single non memory domain and (d) deficits
in more than one non-memory domains.64,65 To date,
there is no consensus on the pharmacological or non
pharmacological treatment of MCI.66
6.

RECOMMENDATIONS

1.

2.
3.
4.
5.

6.

(SUMMARY)

The DSM IV definition of dementia should be used
for diagnostic purposes
An attempt should be made to identify the type of
dementia.
A cognitive evaluation should be done and
documented. We recommend MMSE either English
or Urdu version. The educational background of
the patient should be documented as well for
accurate interpretation of MMSE.
Common treatable causes of memory loss like
vitamin B12 deficiency, hypothyroidism and normal
pressure hydrocephalus should be ruled out.
Neuro-imaging, preferably an MRI of the brain
should be done in order to reach a reasonable
diagnosis. For rapidly progressive dementia the
MRI should include DWI and ADC sequences.
The diagnosis, prognosis, quality of life issues and
the absence of any disease modifying treatment
should be explained to the caregivers.
The decision to initiate a trial of therapy with a
cholinesterase inhibitor or memantine should be
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